3BDO

Cas No.:	890405-51-3
Chemical Name:	3BDO
Synonyms:	3-Benzyl-5-((2-nitrophenoxy)methyl)-dihydrofuran-2(3H)-one;3BDO;3-benzyl-5-((2-nitrophenoxy) methyl)-dihydrofuran-2(3H)-one;3-BDO;BCP29764;s8317;3BDO, >=98% (HPLC);3-Benzyl-5-[(2-nitrophenoxy)methyl]oxolan-2-one
SMILES:	O1C(C(CC2C=CC=CC=2)CC1COC1=CC=CC=C1[N+](=O)[O-])=O
Formula:	C18H17NO5
M.Wt:	327.3313
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:	3BDO is a new mTOR activator which can also inhibit autophagy.
In Vivo:	Immunofluorescence assay reveals that 3BDO treatment increases the level of p-p70S6K and decreases the protein level of ATG13 in plaque endothelium of mice. 3BDO does not affect the phosphorylation of mTOR direct downstream targets p70S6K and 4EBP1. As compare with controls, apoE-/- mice show inhibited endothelium autophagy and apoptosis with 3BDO treatment, so 3BDO protects against endothelium injury in atherosclerosis. 3BDO treatment stabilizes established atherosclerotic lesions in apoE-/- mice. In apoE-/-mice, as compare with controls, with 3BDO treatment, the serum level of IL-6 and IL-8 is significantly decreased[2].
In Vitro:	3BDO is a new mTOR activator which can also inhibit autophagy.
Kinase Assay:	Total protein is obtained from HUVECs by using of IP lysis buffer after treatment with rapamycin (10 μM), 3BDO (60 μM) or both for 6 h. After centrifuging at 4°C, the supernatant is collected and incubated with protein A/G agarose beads and TIA1 antibody or normal mouse IgG as a control at 4°C overnight. The beads are washed 3 times with IP lysis buffer and then eluted with 4×SDS loading buffer. Ser phosphorylation is detected by western blot assay with Ser phosphorylation antibody[1].
Cell Assay:	HUVECs are isolated from umbilical cords and cultured in M199 medium with 20% (v/v) fetal bovine serum and 10 IU/mL fibroblast growth factor 2 (FGF2) in a humidified incubator at 37°C with 5% CO2. Cells up to passage 10 are used for experiments. When HUVECs are grown to 80% confluency, HUVECs are treated with DMSO or 60 µM 3BDO for 24 h, then total RNA is extracted[1].
Animal Administration:	Male apoE-/- mice (8 weeks old) are used in this study. ApoE-/- mice are fed an atherogenic diet (containing 21% fat and 0.15% cholesterol). To avoid the potential confounding effects of variation among batches of diet, a single batch is reserved and used throughout the experiment. Mice at 20 weeks older are divided into 3 groups for treatment (n=8 mice/group) for 8 weeks: control (DMSO), low-dose 3BDO (50 mg/kg/d; 3BDO-L) and high-dose 3BDO (100 mg/kg/d; 3BDO-H). The body weight of mice is measured every week during 3BDO injection. Blood samples are taken from the inferior vena cava, and animals are killed by exsanguination[2].
References:	[1]. Ge D, et al. Identification of a novel MTOR activator and discovery of a competing endogenous RNA regulating autophagy in vascular endothelial cells. Autophagy. 2014 Jun;10(6):957-71. [2]. Peng N, et al. An activator of mTOR inhibits oxLDL-induced autophagy and apoptosis in vascular endothelial cells and restricts atherosclerosis in apolipoprotein E?/? mice. Sci Rep. 2014 Jul 1;4:5519.